Overview
Zucara Therapeutics Inc., based in Toronto, Canada, has raised $20M in a Series B round on Nov 1, 2024, with participation from Investor 97. The company headline 36. The round will be used to accelerate product development, expand the team, and scale go-to-market operations.
Operating in the industry 36 sector, Zucara Therapeutics Inc. is positioned to capitalize on growing demand for innovative solutions in this space. The company was founded in 0 by Michael Midmer. Michael brings deep domain expertise and a track record of execution that attracted investor confidence in this round. With fresh capital, the company is expected to invest heavily in R&D and talent acquisition, signaling a period of aggressive growth ahead.
Market Outlook
This funding positions Zucara Therapeutics Inc. as one to watch in the industry 36 landscape. As the company scales, it will likely become an increasingly attractive partner — and customer — for B2B vendors looking to sell into well-funded, growth-stage companies. The post-raise window of 60-90 days is typically when startups are most receptive to new tools, services, and partnerships.
Why contact Zucara Therapeutics Inc. now
Zucara Therapeutics Inc. just closed $20M in Series B funding — which means they're actively scaling their team, upgrading their tech stack, and looking for vendors who can help them move fast. Companies at this stage typically make purchasing decisions within 60-90 days of closing a round. If you sell to industry 36 companies, this is your window to reach out before competitors do.
Founders & Contacts
Investors
Company Facts
| Company | Zucara Therapeutics Inc. |
| Amount Raised | $20M |
| Funding Round | Series B |
| Date Raised | Nov 1, 2024 |
| Founded | 0 |
| Industry | Industry 36 |
| Founders | Michael Midmer |
| HQ Location | Toronto, Canada |
Get Verified Founder Emails
Access verified email addresses and contact details for Zucara Therapeutics Inc.'s founders and thousands of other funded startups.
Start Free Trial